Partner News

Our partnership strategy has enabled us to build a broad product pipeline and to create an annuity of license fees, milestone payments and royalty revenues while limiting development expenses. This strategy enables us to remain focused on research and development and to discover new drugs and expand our and our partners' pipelines. Please check here for updates on news, event participation and important scientific publications from our partners.

News

2013-05-01	OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer
2013-05-01	ATL1102 for Multiple Sclerosis -Toxicology Study to Commence
2013-04-30	OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment
2013-04-24	Achaogen Awarded $60M Contract Option by BARDA for the Clinical Development of Plazomicin
2013-04-11	OncoGenex Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer
2013-04-10	ATL1103 Phase II trial - dosing of patients commences
2013-03-22	ATL1103 Phase I Trial Data to be Presented at Acromegaly Conference
2013-03-19	ATL1102 Development and Agreement Update
2013-02-12	OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
2013-02-12	ATL1102 - US Patent Allowance and Development Progress
2013-01-25	ATL1103 Phase II trial - patient enrolment commences
2012-12-19	OncoGenex Announces Initiation of Randomized Phase 2 "PACIFIC" Study of OGX-427 in combination with Zytiga® in Men with Metastatic Castrate-Resistant Prostate Cancer
2012-11-07	Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
2012-11-06	OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
2012-11-05	Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
2012-11-03	Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
2012-10-04	Regulus Announces Pricing of Initial Public Offering
2012-09-27	OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer
2012-08-28	Alnylam and Monsanto Form Strategic Alliance
2012-08-20	Regulus Files Registration Statement for Proposed Initial Public Offering
2012-08-15	Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
2012-08-14	Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
2012-08-07	OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
2012-08-02	OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
2012-07-18	Alliance and License Agreement Executed to Further Develop ATL1102
2012-07-10	OncoGenex Announces Clinical Development Plans for Custirsen in Non-Small Cell Lung Cancer
2012-06-29	ANP Enters Negotiation on Licensing Proposal for ATL1103
2012-06-04	Data from a Phase 2 Study Presented at the 2012 ASCO Annual Meeting Continues to Show Early Activity of OGX-427 in Patients with Prostate Cancer
2012-05-07	Funding Secured for ATL1103 Phase II Trial and Pipeline Partnering Activities

About Isis

We know that sick people depend on us, and we have the technology to change the way diseases are treated.

Learn More

Strategic Alliances

Our business strategy is to do what we do best — to discover antisense drugs. We look for the right partners to help us produce and commercialize our drugs, and we've had tremendous success with both small and global pharmaceutical partners.

Learn More